Date published: 2026-8-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

SLC35F2 CRISPR/Cas9 KO Plasmid (h): sc-406765

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • SLC35F2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SLC35F2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    SLC35F2 CRISPR/Cas9 KO Plasmid (h)

    sc-406765
    20 µg
    $397.00

    Overview

    SLC35F2 encodes a predicted multi-pass membrane transporter localized to intracellular membranes, with evidence supporting a role in solute trafficking that influences cellular uptake and compartmental distribution of small molecules. As a member of the SLC35 family, SLC35F2 is linked to membrane transport processes that can impact metabolic homeostasis, organelle function, and cellular stress responses. Altered transporter activity can modulate intracellular exposure to xenobiotics and endogenous metabolites, connecting SLC35F2 to mechanisms relevant to pharmacology and cancer cell biology. Accordingly, SLC35F2 is frequently investigated in studies of transport-dependent sensitivity, cellular fitness, and pathway-level determinants of compound response.

    SLC35F2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLC35F2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLC35F2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLC35F2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SLC35F2 protein expression.

    This CRISPR knockout system enables efficient generation of SLC35F2-deficient cell models for investigation of SLC35F2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting SLC35F2 exon(s) critical for SLC35F2 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple SLC35F2 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by SLC35F2 CRISPR/Cas9 KO Plasmid (h) and SLC35F2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SLC35F2 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by SLC35F2 HDR Plasmid (h) and SLC35F2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SLC35F2 homology arms to support homology-directed repair at defined SLC35F2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.